Literature DB >> 26339338

MicroRNA-497 induces cell apoptosis by negatively regulating Bcl-2 protein expression at the posttranscriptional level in human breast cancer.

Chuankui Wei1, Qifeng Luo2, Xiaoguo Sun3, Dengfeng Li2, Hongming Song2, Xiaoyu Li2, Jialu Song2, Kaiyao Hua2, Lin Fang2.   

Abstract

Many studies have demonstrated that microRNAs (miRNAs) may play vital roles in the development of breast cancer. The aim of this study was to examine the expression levels of miR-497 in human breast cancer and investigate whether its potential roles involved targeting Bcl-2. Real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR) was used to examine the expression levels of miR-497 in 48 breast cancer specimens and six breast cancer cell lines. MTT assay, colony formation assay, and flow cytometry were conducted to explore the potential functions of miR-497 in human MDA-MB-231 breast cancer cells. Correlation analysis and dual-luciferase reporter assay were performed to validate whether Bcl-2 was a direct target of miR-497. The effects of modulating miR-497 on endogenous levels of Bcl-2 were subsequently confirmed via qRT-PCR and western blot. MTT assay, colony formation assay and flow cytometry were used to indicate the roles of endogenous Bcl-2 in breast cancer cells. miR-497 expression levels were significantly decreased in human breast cancer specimens and cell lines (P<0.05). Overexpression of miR-497 in breast cancer cells suppressed cell proliferation and induced apoptosis. Correlation analysis indicated that miR-497 was highly inversely correlated with Bcl-2 protein expression in breast cancer specimens. Dual-luciferase reporter assays confirmed that Bcl-2 was a direct target of miR-497. qRT-PCR and western blot showed that miR-497 negatively regulated Bcl-2 protein expression but had no impact on mRNA expression of Bcl-2. Knockdown of Bcl-2 expression in MDA-MB-231 cells significantly suppressed cell proliferation and promoted apoptosis. Our study suggests that miR-497 may act as a breast cancer suppressor through negative regulation of Bcl-2 protein expression at the posttranscriptional levels. Therefore, targeting miR-497 may provide a novel strategy for the diagnosis and treatment of patients with this lethal disease.

Entities:  

Keywords:  Bcl-2; apoptosis; breast cancer; miR-497

Mesh:

Substances:

Year:  2015        PMID: 26339338      PMCID: PMC4555666     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  35 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  BCL2 expression in chronic lymphocytic leukemia: lack of association with the BCL2 938A>C promoter single nucleotide polymorphism.

Authors:  Aneela Majid; Olga Tsoulakis; Renata Walewska; Stefan Gesk; Reiner Siebert; D Ben J Kennedy; Martin J S Dyer
Journal:  Blood       Date:  2007-10-24       Impact factor: 22.113

3.  BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma.

Authors:  Javeed Iqbal; Vishala T Neppalli; George Wright; Bhavana J Dave; Douglas E Horsman; Andreas Rosenwald; James Lynch; Christine P Hans; Dennis D Weisenburger; Timothy C Greiner; Randy D Gascoyne; Elias Campo; German Ott; H Konrad Müller-Hermelink; Jan Delabie; Elaine S Jaffe; Thomas M Grogan; Joseph M Connors; Julie M Vose; James O Armitage; Louis M Staudt; Wing C Chan
Journal:  J Clin Oncol       Date:  2006-01-17       Impact factor: 44.544

4.  Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked.

Authors:  J Yang; X Liu; K Bhalla; C N Kim; A M Ibrado; J Cai; T I Peng; D P Jones; X Wang
Journal:  Science       Date:  1997-02-21       Impact factor: 47.728

5.  MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms.

Authors:  Keitaro Kojima; Yasunori Fujita; Yoshinori Nozawa; Takashi Deguchi; Masafumi Ito
Journal:  Prostate       Date:  2010-10-01       Impact factor: 4.104

6.  Translocation t(14;18)/IGH-BCL2 in gastrointestinal follicular lymphoma: correlation with clinicopathologic features in 48 patients.

Authors:  Shunichi Yanai; Shotaro Nakamura; Morishige Takeshita; Kouhei Fujita; Minako Hirahashi; Keisuke Kawasaki; Koichi Kurahara; Yuji Sakai; Takayuki Matsumoto
Journal:  Cancer       Date:  2010-12-29       Impact factor: 6.860

7.  miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells.

Authors:  Lin Xia; Dexin Zhang; Rui Du; Yanglin Pan; Lina Zhao; Shiren Sun; Liu Hong; Jie Liu; Daiming Fan
Journal:  Int J Cancer       Date:  2008-07-15       Impact factor: 7.396

8.  MicroRNA in the molecular mechanism of the circadian clock in mammals.

Authors:  Cheng Chu; Zhongxin Zhao
Journal:  Front Biosci (Landmark Ed)       Date:  2013-01-01

9.  Numerical modelling of microRNA-mediated mRNA decay identifies novel mechanism of microRNA controlled mRNA downregulation.

Authors:  Jiri Vohradsky; Josef Panek; Tomas Vomastek
Journal:  Nucleic Acids Res       Date:  2010-04-05       Impact factor: 16.971

10.  MiRNA-26b inhibits proliferation by targeting PTGS2 in breast cancer.

Authors:  Jia Li; Xiangjie Kong; Junfeng Zhang; Qifeng Luo; Xiaoyu Li; Lin Fang
Journal:  Cancer Cell Int       Date:  2013-02-01       Impact factor: 5.722

View more
  13 in total

1.  Tumor-suppressive microRNA-452 inhibits migration and invasion of breast cancer cells by directly targeting RAB11A.

Authors:  Wanjun Li; Guoyin Li; Zhigang Fan; Tao Liu
Journal:  Oncol Lett       Date:  2017-06-20       Impact factor: 2.967

2.  miR-497 and 219 in blood aid meningioma classification.

Authors:  Ahmed Abdelrahman; Caterina Negroni; Felix Sahm; Claire L Adams; Tadeja Urbanic-Purkart; Michael Khalil; Raffaellla Vergura; Cristina Morelli; Clemens Oliver Hanemann
Journal:  J Neurooncol       Date:  2022-09-08       Impact factor: 4.506

3.  MicroRNA-497 downregulation contributes to cell proliferation, migration, and invasion of estrogen receptor alpha negative breast cancer by targeting estrogen-related receptor alpha.

Authors:  Li Han; Bo Liu; Lixi Jiang; Junyan Liu; Shumei Han
Journal:  Tumour Biol       Date:  2016-07-25

4.  miR-497 inhibits epithelial mesenchymal transition in breast carcinoma by targeting Slug.

Authors:  Zhihao Wu; Xiangli Li; Xuehong Cai; Chenggang Huang; Min Zheng
Journal:  Tumour Biol       Date:  2015-12-23

5.  Twist promotes angiogenesis in pancreatic cancer by targeting miR-497/VEGFA axis.

Authors:  An Liu; Chenggang Huang; Xuehong Cai; Jia Xu; Dinghua Yang
Journal:  Oncotarget       Date:  2016-05-03

Review 6.  Post-Transcriptional Regulation of Anti-Apoptotic BCL2 Family Members.

Authors:  Jia Cui; William J Placzek
Journal:  Int J Mol Sci       Date:  2018-01-20       Impact factor: 5.923

7.  Up-regulation of miR-497 confers resistance to temozolomide in human glioma cells by targeting mTOR/Bcl-2.

Authors:  Danhua Zhu; Ming Tu; Bo Zeng; Lin Cai; Weiming Zheng; Zhipeng Su; Zhengquan Yu
Journal:  Cancer Med       Date:  2017-01-08       Impact factor: 4.452

8.  miR-497 inhibited proliferation, migration and invasion of thyroid papillary carcinoma cells by negatively regulating YAP1 expression.

Authors:  Hui Cheng; Hui Dong; Jianlin Feng; Hongyan Tian; Haixia Zhang; Lina Xu
Journal:  Onco Targets Ther       Date:  2018-08-10       Impact factor: 4.147

9.  MicroRNA-34a: A Key Regulator in the Hallmarks of Renal Cell Carcinoma.

Authors:  Eman A Toraih; Afaf T Ibrahiem; Manal S Fawzy; Mohammad H Hussein; Saeed Awad M Al-Qahtani; Aly A M Shaalan
Journal:  Oxid Med Cell Longev       Date:  2017-09-20       Impact factor: 6.543

Review 10.  miR-497 expression, function and clinical application in cancer.

Authors:  Gang Yang; Guangbing Xiong; Zhe Cao; Suli Zheng; Lei You; Taiping Zhang; Yupei Zhao
Journal:  Oncotarget       Date:  2016-08-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.